

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number

WO 2025/015318 A9

(43) International Publication Date
16 January 2025 (16.01.2025)

(51) International Patent Classification:

C12N 5/07 (2010.01) C12N 5/0783 (2010.01)
C07K 14/54 (2006.01)

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:

PCT/US2024/037938

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:

12 July 2024 (12.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/513,550	13 July 2023 (13.07.2023)	US
63/622,008	17 January 2024 (17.01.2024)	US
63/562,210	06 March 2024 (06.03.2024)	US
63/649,302	17 May 2024 (17.05.2024)	US

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

27 February 2025 (27.02.2025)

(48) Date of publication of this corrected version:

11 December 2025 (11.12.2025)

(15) Information about Correction:

see Notice of 11 December 2025 (11.12.2025)

(71) Applicant: IOVANCE BIOTHERAPEUTICS, INC.
[US/US]; 825 Industrial Road, Suite 400, San Carlos, CA
94070 (US).

(72) Inventors: ZHANG, Yongliang; 1436 Deerbourne Dr.,
Wesley Chapel, FL 33543 (US). INNAMARATO,
Pasquale, Patrick, IV; 1044 Anchor Bend Drive, Ruskin,
FL 33570 (US). GILBERT, Nathan; 518 Golden Rain-
tree Place, Brandon, FL 33510 (US). YIN, Hequn; 15471
Martinmeadow Dr., Lithia, FL 33547 (US). VOGT, Fred-
erick G.; 2120 Hemlock Road, West Norriton, PA 19401
(US). HALL, Sean; 1520 N. Pierce St., Unit 8, Tampa,
FL 33602 (US). ERICKSON, Tim; 1321 Sands Ter W,
Clearwater, FL 33764 (US). PULIDO, Alvaro, De Mingo;
19204 Hempstone Avenue, Poolesville, MD 20837 (US).

(74) Agent: LOVE, Richard B. et al.; Iovance Biotherapeutics,
Inc., 825 Industrial Road, Suite 100, San Carlos, CA 94070
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(54) Title: CYTOKINE ENCODING LENTIVIRAL VECTORS AND USES THEREOF FOR MAKING TUMOR INFILTRATING LYMPHOCYTES

(57) Abstract: Provided herein are cytokine-encoding nucleic acid molecules, such as recombinant expression vectors, and uses thereof to make modified tumor infiltrating lymphocytes (TILs), wherein the modified TILs include one or more immunomodulatory agents (e.g. cytokines) associated with their cell surface. The immunomodulatory agents associated with the TILs provide a localized immunostimulatory effect that can advantageously enhance TIL survival, proliferation and/or anti-tumor activity in a patient recipient. As such, the compositions and methods disclosed herein provide effective cancer therapies.

WO 2025/015318 A9